Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound

US5830880A · kind A · utility

Assignee

• Hoechst GmbH · DE

Inventors

• Hans-Harald Sedlacek · Marburg, DE
• Klaus Bosslet · Marburg, DE
• Rolf Muller · Marburg, DE

Key dates

• Filing date: Apr 18, 1997
• Grant date: Nov 3, 1998
• Expiry date: Apr 18, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/85
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.